Bio-Rad Laboratories (NYSE:BIO) Receives New Coverage from Analysts at UBS Group

UBS Group started coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) in a research report sent to investors on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $395.00 price objective on the medical research company’s stock. Separately, StockNews.com cut shares of Bio-Rad Laboratories from a buy rating to a […]

Related Keywords

United States ,Canada ,America ,Michael Crowley ,Ubs Group ,Raleigh Capital Management Inc ,Securities Exchange Commission ,Atlas Capital Advisors ,Pacific Center ,Bio Rad Laboratories Inc ,Bio Rad Laboratories Company Profile ,Financial Services ,Bio Rad Laboratories ,Free Report ,Moderate Buy ,Rad Laboratories ,Get Free Report ,Exchange Commission ,Finance Advisors ,Capital Management ,Life Science ,Clinical Diagnostics ,Bio Rad Laboratories Daily ,Nyse Bio ,Bio ,Medical ,09057220 ,Initiated Coverage ,Ubs Group Ag ,